Authors Jaune E, Cavazza E, Ronco C, Grytsai O, Abbe P, Tekaya N, Zerhouni M, Beranger G, Kaminski L, Bost F, Gesson M, Tulic M, Hofman P, Ballotti R, Passeron T, Botton T, Benhida R, Rocchi S
Cell death & disease Jan 2021
Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.Authors Cheli Y, Tulic MK, El Hachem N, Nottet N, Jacquel A, Gesson M, Strub T, Bille K, Picard-Gauci A, Montaudié H, Beranger GE, Passeron T, Close P, Bertolotto C, Ballotti R
Molecular cancer Jan 2021
Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease.Authors Pandiani C, Strub T, Nottet N, Cheli Y, Gambi G, Bille K, Husser C, Dalmasso M, Béranger G, Lassalle S, Magnone V, Pédeutour F, Irondelle M, Maschi C, Nahon-Estève S, Martel A, Caujolle JP, Hofman P, LeBrigand K, Davidson I, Baillif S, Barbry P, Ballotti R, Bertolotto C
Cell death and differentiation Jan 2021
FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells.Authors Habel N, El-Hachem N, Soysouvanh F, Hadhiri-Bzioueche H, Giuliano S, Nguyen S, Horák P, Gay AS, Debayle D, Nottet N, Béranger G, Paillerets BB, Bertolotto C, Ballotti R
Cell death and differentiation Jan 2021
ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.Authors Cheli Y, Tulic MK, El Hachem N, Nottet N, Jacquel A, Gesson M, Strub T, Bille K, Picard-Gauci A, Montaudié H, Beranger GE, Passeron T, Close P, Bertolotto C, Ballotti R
Molecular cancer Jan 2021
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?Authors Ballotti R, Cheli Y, Bertolotto C
Molecular cancer Dec 2020
Regulation of Melanogenesis by the Amino Acid Transporter SLC7A5.Authors Gaudel C, Soysouvanh F, Leclerc J, Bille K, Husser C, Montcriol F, Bertolotto C, Ballotti R
The Journal of investigative dermatology Nov 2020
Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives.Authors Martel A, Baillif S, Nahon-Esteve S, Gastaud L, Bertolotto C, Roméo B, Mograbi B, Lassalle S, Hofman P
Cancers Nov 2020
The “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”.Authors Strub T, Ballotti R, Bertolotto C
Theranostics Jan 2020
Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.Authors Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, Gagnon A, Judson RL, Ballotti R, Ribas A, Herlyn M, Rocchi S, Brown KM, Hayward NK, Yeh I, Bastian BC
Cell reports Oct 2019